RxDoctor Payments Data

Joshua Kamins, MD

Neurology · Los Angeles, CANPI 1689930034

Payments from drug & device makers

$40,757in general payments, 2019–2025

Across 50 payments — averaging $815.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$38K
  • H. Lundbeck A S$3K
  • AbbVie$426
  • Amgen$125
  • Impel Pharmaceuticals Inc.$12

What the payments were for

  • Consulting fees$10,65126%
  • Speaking & faculty fees$29,25072%
  • Travel & lodging$900%
  • Food & beverage$7542%
  • Education$120%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lundbeck LLC44$37,644
H. Lundbeck A S2$2,550
AbbVie2$426
Amgen1$125
Impel Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,757 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$183,902
Medicare patients
156
Services billed
18,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant58$74,549
Nurtec OdtRimegepant Sulfate47$61,366
Ajovy AutoinjectorFremanezumab-Vfrm38$42,879
QuliptaAtogepant23$39,180
Emgality PenGalcanezumab-Gnlm36$29,638
ReyvowLasmiditan Succinate16$23,793
Aimovig AutoinjectorErenumab-Aooe24$22,913
Dihydroergotamine Mesylate11$10,884
ImitrexSumatriptan Succinate13$10,056
Almotriptan Malate13$2,962
Memantine Hcl45$2,471
Duloxetine Hcl55$1,718
Sumatriptan Succinate27$1,178
Candesartan Cilexetil17$990
RizatriptanRizatriptan Benzoate60$854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$426$113,72981 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →